1. Introduction

   • Roger Williams

   Interview 23 October 2012 Pages: 1 - 1

2. Pathophysiology and Epidemiology of Portal Hypertension

   • Hidemasa Okumura
   • Takumi Aramaki
   • Yasumi Katsuta

   Section 1 23 October 2012 Pages: 2 - 12

3. Morbidity and Mortality of Portal Hypertension

   • Joanna B. Ready
   • William G. Rector

   Section 1 23 October 2012 Pages: 13 - 24

4. Surgery and Sclerotherapy for Treatment of Portal Hypertension and Oesophageal Varices

   • A. K. Burroughs

   Section 1 23 October 2012 Pages: 25 - 29

5. A Randomised Controlled Study of Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis

   • Didier Lebrec
   • Thierry Poynard
   • Jean-Pierre Benhamou

   Section 1 23 October 2012 Pages: 30 - 34

6. β Blockers in the Secondary Prevention of Gastrointestinal Haemorrhage in Well-Compensated Cirrhotics

   • M. Tommasini
   • R. de Franchis
   • M. Colombo

   Section 2 23 October 2012 Pages: 35 - 41

7. Comparison of Propranolol with Injection Sclerotherapy in Prevention of Rebleeding from Oesophageal Varices in Cirrhotic Patients

   • David Westaby
   • R. Polson
   • Roger Williams

   Section 1 23 October 2012 Pages: 42 - 46

8. Discussion: Section 1

   Section 1 23 October 2012 Pages: 47 - 47

9. A Randomised Controlled Trial of Propranolol for the Prevention of Initial Bleeding in Cirrhotic Patients with Portal Hypertension

   • Luigi Pagliaro
   • Linda Pasta
   • Gennaro D’Amico

   Section 2 23 October 2012 Pages: 48 - 51

10. Propranolol in the Primary Prevention of Upper Gastrointestinal Tract Haemorrhage in Patients with Cirrhosis of the Liver and Oesophageal Varices

    • Jean-Pierre Pascal
    • Paul Calès

    Section 2 23 October 2012 Pages: 52 - 61

11. β-Blockers in Portal Hypertension

    • J. A. Lewis
    • J. M. Davis
    • H. A. Cameron

    Section 2 23 October 2012 Pages: 62 - 69

12. Safety of Propranolol in Portal Hypertension

    • Peter C. Hayes

    Section 2 23 October 2012 Pages: 70 - 73

13. Discussion: Section 2

    Section 2 23 October 2012 Pages: 74 - 76